Research programme: tubulysin cancer therapeutics - Calando Pharmaceuticals/R&D-Biopharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Insert Therapeutics; R&D-Biopharmaceuticals
- Class
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 09 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section